(9S,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxo-2,3-dihydropyridin-1-yl]-10-fluoro-3,9-dimethyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one;2,2,2-trifluoroacetic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: (9S,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxo-2,3-dihydropyridin-1-yl]-10-fluoro-3,9-dimethyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one;2,2,2-trifluoroacetic acid
• 化学式: C31H28Cl2F4N8O4
• 分子量: 723.5
• InChiKey: OGLNSULKXAUVOM-SLAQUOQGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.07
• 重原子数：
  49
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  148
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• Macrocyclic factor XIa inhibitors bearing heterocyclic groups
  申请人：Bristol-Myers Squibb Company

  公开号：US10273236B2

  公开（公告）日：2019-04-30

  The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式 (Ia) 的化合物： 或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子 XIa 抑制剂或 FXIa 和血浆钙激酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗血栓栓塞性和/或炎症性疾病的方法。
• MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES
  申请人：Bristol-Myers Squibb Company

  公开号：US20170342071A1

  公开（公告）日：2017-11-30

  The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.